NovaBridge Biosciences (NBP)
NASDAQ: NBP · Real-Time Price · USD
2.590
+0.040 (1.57%)
Mar 27, 2026, 10:47 AM EDT - Market open
NovaBridge Biosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
32
Market Cap
298.60M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 632.00K | 2.18M | - |
| Dec 31, 2022 | -1.55M | -15.41M | - |
| Dec 31, 2021 | 13.86M | -222.44M | -94.14% |
| Dec 31, 2020 | 236.29M | 231.99M | 5,384.30% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Foghorn Therapeutics | 30.91M |
| LENZ Therapeutics | 19.09M |
| Crescent Biopharma | 10.84M |
| Armata Pharmaceuticals | 5.05M |
| AC Immune | 4.51M |
| Surrozen | 3.48M |
| Avalo Therapeutics | 59.00K |
NBP News
- 11 days ago - NovaBridge Announces Productive FDA Type B Meeting on Potential Accelerated Approval Pathway for Givastomig in Gastric Cancer - GlobeNewsWire
- 17 days ago - NovaBridge Biosciences (NBP) Discusses Phase 2a Clinical Data and Development Plan for VIS-101 in Wet Age-Related Macular Degeneration Transcript - Seeking Alpha
- 18 days ago - Mid-Cap NovaBridge Biosciences Stock Jumps Fueled By Positive Study Data In Eye Disease - Benzinga
- 18 days ago - NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study - GlobeNewsWire
- 24 days ago - NovaBridge to Host Business Update Call to Review Phase 2a Data for VIS-101 in Wet AMD on Monday, March 9, 2026 - GlobeNewsWire
- 25 days ago - NovaBridge to Present at the Leerink Partners 2026 Global Healthcare Conference - GlobeNewsWire
- 5 weeks ago - NovaBridge Appoints Biotech Leader, Emmett T. Cunningham, Jr, MD, PhD, MPH, as Vice Chairman of the Board to Further Accelerate Global Biotech Platform - GlobeNewsWire
- 5 weeks ago - NovaBridge Doses First Patient in Global, Randomized Phase 2 Study of Givastomig Combined with Immunochemotherapy in Patients with 1L Metastatic Gastric Cancer - GlobeNewsWire